19. November 2009 23:21
"Providing access to contraception for 215 million women, mainly in developing countries, would help to stabilize population growth and significantly reduce the effects of climate change," according to a report released Wednesday by the United Nations Population Fund (UNFPA), Nature News reports (Gilbert, 11/18).
[More]
17. November 2009 03:13
BioSante Pharmaceuticals, Inc., a specialty pharmaceutical company developing products for female sexual health, including LibiGel® for the treatment of hypoactive sexual desire disorder (HSDD), applauds the efforts of Boehringer Ingelheim to develop a therapy to treat this unmet medical need.
[More]
ce48eec0-1716-4988-864d-6c11cc5f5d0b|0|.0
Posted in: Medical Condition News | Pharmaceutical News
Tags: Brain, Calcium, Cancer, Cell, Contraception, Dopamine, Drug Delivery, Erectile Dysfunction, Estradiol, Estrogen, H1N1, Menopause, New Drug Application, Serotonin, Sexual Dysfunction, Sleep, Swine Flu, Testosterone, Vaccine
16. November 2009 23:15
Data from pivotal Phase III clinical trials demonstrate that flibanserin 100mg increased the number of satisfying sexual events (SSE) and sexual desire (the co-primary endpoints) while decreasing the distress associated with Hypoactive Sexual Desire Disorder (HSDD).
[More]
16. November 2009 09:04
Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, announced today that Lysteda(TM) (tranexamic acid) oral tablets has received U.S. Food and Drug Administration (FDA) approval for treatment of women suffering from cyclic heavy menstrual bleeding (HMB), also known as menorrhagia.
[More]
16. November 2009 03:29
Over the last decade, the maternal mortality rate has dropped by 50 percent in some former Soviet bloc and Balkan countries, according to a U.N. Population Fund (UNFPA) report released Thursday, Agence France-Presse/France24 reports.
[More]
16. November 2009 00:07
The U.S. Food and Drug Administration today approved Lysteda tablets (tranexamic acid), the first non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). Lysteda works by stabilizing a protein that helps blood to clot.
[More]
13. November 2009 06:40
Faculty of 1000 reviewers examine a study from New Zealand on whether prolonged exposure to the father's semen protects new mothers against pre-eclampsia and having an undersized baby.
[More]
11. November 2009 03:12
Emory University Rollins School of Public Health researchers will present Nov. 11 on a range of topics at the American Public Health Association's annual meeting in Philadelphia, including a study that found reduced absenteeism among employees participating in a large-scale worksite wellness program.
[More]
11. November 2009 00:05
In follow-up coverage to the WHO's report on women's health, several news outlets examine the impact HIV/AIDS is having on women around the world. "In its first study of women's health, the World Health Organization said yesterday that the AIDS virus is the leading cause of death and disease among women between the ages of 15 and 44," the Associated Press/Boston Globe reports (11/10).
[More]
10. November 2009 03:02
Conceptus, Inc., developer of the Essure® procedure, the first proven non-incisional permanent birth control method available, today announced that the United Stated District Court, Northern District of California has denied Conceptus’ motion for a preliminary injunction prohibiting Hologic, Inc. from importing, using, selling or offering to sell the Adiana system in the United States.
[More]
10. November 2009 01:48
The lives of almost 4 million women, newborns, and children in sub-Saharan Africa could be saved every year if well-established, affordable health care interventions reached 90 percent of families, according to a joint report by the national science academies of seven African countries.
[More]
9. November 2009 07:52
Warner Chilcott plc today announced its results for the quarter ended September 30, 2009. Revenue in the quarter ended September 30, 2009 increased 9.0% to $252.8 million over the prior year quarter. The primary drivers of the increase in revenue in the quarter were the net sales of LOESTRIN 24 FE and ESTRACE Cream which were partially offset by net sales declines of other products, primarily TACLONEX.
[More]
9. November 2009 03:34
An Indiana University study involving 2,453 women ages 18 to 68 found that lubricant use during sexual activity alone or with a partner contributed to higher ratings of pleasurable and satisfying sex.
[More]
5. November 2009 01:59
A study at Johns Hopkins Children's Center found that girls diagnosed with pelvic inflammatory disease (PID) who watched a short educational video were three times more likely to discuss their condition with their partners and to ensure partner treatment than girls diagnosed and treated without seeing the film.
[More]
3. November 2009 03:02
Schering-Plough Corporation today reported that interim results from an ongoing Phase IIa study of narlaprevir (SCH 900518), its investigational, once-daily protease inhibitor, demonstrated potent antiviral activity in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1.
[More]
1a7fbbff-144f-40e7-b2ff-2a96b6917170|1|5.0
Posted in: Drug Trial News | Disease/Infection News
Tags: Anemia, Angina, Angioedema, Anorexia, Anxiety, Arthritis, Blindness, Bone, Bone Marrow, Cancer, Cardiomyopathy, Cell, Cellulitis, Cirrhosis, Contraception, Creatinine, Depression, Dyspnea, Edema, Emphysema, Fibrosis, Gastroenteritis, Gout, Headache, Hepatitis C, Hepatology, Hyperglycemia, Hypersensitivity, Hyperthyroidism, Hypertriglyceridemia, Hypothyroidism, Insomnia, Liver Cancer, Lupus, Nausea, Neuropathy, Neutropenia, Pancreatitis, Peginterferon alfa, Pneumonia, Pregnancy, Psoriasis, Psychosis, Pulmonary Hypertension, Rheumatoid Arthritis, Ribavirin, Ritonavir, Sarcoidosis, Sepsis, Thalassemia, Thrombocytopenia, Thrombosis, Transient Ischemic Attack, Urticaria, Vasculitis, Virus, Vomiting, Weight Loss
Subscribe